Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary DiseasePatients Hospitalized for a COPD Exacerbation
- Interventions
- Other: PEP
- Registration Number
- NCT02035293
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
A standardized diagnostic strategy of pulmonary embolism will be applied to eligible patients, incorporating a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a multidetector-row CT angiography thoracic and venous ultrasound of the lower limbs. All the patient with a pulmonary embolism diagnosed or not, will be followed for 3 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 750
- Patients hospitalized for a COPD exacerbation
- COPD previously diagnosed
- Allergy to iodinated contrast
- Creatinine clearance < 30 mL / min
- Patient hospitalized for exacerbation of COPD for more than 48 hours
- Pneumothorax
- Exams impossible to be performed
- Pregnancy
- Life expectancy < 3 months
- Patients already receiving anticoagulant therapy for another reason (mechanical valve, cardiac arrhythmia).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description PEP PEP No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only following exams must be performed: a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a chest multidetector-row CT angiography and venous ultrasound of the lower limbs
- Primary Outcome Measures
Name Time Method Frequency of pulmonary embolism in patients hospitalized for a clinical exacerbation of COPD. 27 months
- Secondary Outcome Measures
Name Time Method The rate of pulmonary embolism diagnosed during the 3 month follow-up in patients whom pulmonary embolism was initially excluded when they've been included in the study 27 months
Trial Locations
- Locations (7)
CHU
🇫🇷Angers, France
HIA
🇫🇷Brest, France
CHRU de Brest
🇫🇷Brest, France
CHU Clermont-Ferrand
🇫🇷Clermont-Ferrand, France
CH de Cornouaille Quimper
🇫🇷Quimper, France
Hôpital Nord
🇫🇷St-Etienne, France
Hôpital Européen Georges Pompidou
🇫🇷Paris, France